03rd week of 2012 patent applcation highlights part 33 |
Patent application number | Title | Published |
20120014832 | Ni-BASED SINGLE CRYSTAL SUPERALLOY - The Ni-based single crystal alloy disclosed here is a single crystal and has a chemical composition containing, as % by mass,
| 2012-01-19 |
20120014833 | FREE RADICAL INITIATOR COMPOSITIONS CONTAINING T-BUTYL HYDROPEROXIDE AND THEIR USE - A composition comprising (a) an epoxy resin; and (b) a hydroperoxide composition comprising a t-butyl hydroperoxide solution that contains no more than 7 weight percent water, and use of the compositions to prepare foundry shapes, the foundry shapes prepared by the process, the use of the foundry shapes to prepare cast metal articles, and the cast metal articles prepared by the process. | 2012-01-19 |
20120014834 | METHOD AND APPARATUS FOR MANUFACTURING ALUMINUM ALLOY STRIP FOR LITHOGRAPHIC PRINTING PLATES - An apparatus for manufacturing aluminum alloy strip for a lithographic printing plate supports includes a filter, a launder connected to the filter, a liquid level controller connected to the launder, and a melt feed nozzle connected to the liquid level controller. The liquid level controller includes a step to trap settled particles within an aluminum melt which forms the alloy strip. The launder has a length L (m) which satisfies the condition | 2012-01-19 |
20120014835 | OPTICAL SYSTEM FOR CHEMICAL AND/OR BIOCHEMICAL REACTIONS - An apparatus for detecting spectra in light emanating from chemical or biochemical reactions occurring in at least one reaction vessel ( | 2012-01-19 |
20120014836 | MANIPULATION OF MAGNETIC PARTICLES IN A BIOLOGICAL SAMPLE - The present invention relates to a microfluidic device, to be used with a processing device comprising a magnetic supplier, the microfluidic device comprising: —a chamber arranged to receive a biological sample and to comprise at least one magnetic particle, and—storing means for storing information comprising a magnetic protocol in a form readable by the processing device, wherein the magnetic supplier being able to generate magnetic forces on the magnetic particle(s) according to this magnetic protocol read from the storing means. The invention relates also the said processing device and to a system comprising said microfluidic device and said processing device, as well as a method of manipulating the magnetic particles according to said magnetic protocol. | 2012-01-19 |
20120014837 | ILLUMINATION OF INTEGRATED ANALYTICAL SYSTEMS - An analytical device including an optically opaque cladding, a sequencing layer including a substrate disposed below the cladding, and a waveguide assembly for receiving optical illumination and introducing illumination into the device. The illumination may be received from a top, a side edge, and a bottom of the device. The waveguide assembly may include a nanoscale aperture disposed in the substrate and extending through the cladding. The aperture defines a reaction cell for receiving a set of reactants. In various aspects, the device includes a sensor element and the illumination pathway is through the sensor element. Waveguides and illumination devices, such as plasmonic illumination devices, are also disclosed. Methods for forming and operating the devices are also disclosed. | 2012-01-19 |
20120014838 | CONTROLLER FOR PLANT - A controller for a plant that controls a controlled variable for the plant in accordance with estimated values, allowing to reduce any error in the estimated values that is caused by solid variation or aging of the plant. A controller for an exhaust emission control system has an estimated Inert-EGR value calculation section ( | 2012-01-19 |
20120014839 | ACTIVE CO NEUTRALIZING DEVICE - An active CO neutralizing device includes a CO sensing unit, a control unit, an alarm unit and an ozone releasing unit and serves to detect a concentration of carbon monoxide in the air and to automatically release ozone to react with carbon monoxide when the detected concentration of carbon monoxide is in excess of a preset threshold so as to neutralize and thereby dilute carbon monoxide in order to minimize the risk of carbon monoxide poisoning and allow more time for rescue. | 2012-01-19 |
20120014840 | ION GENERATION APPARATUS - An ion generation apparatus includes: an air blower including a motor and two impellers attached to the output shafts projecting respectively from both sides of the motor; and two ducts through which air sent through rotation of the two impellers is individually allowed to flow in the same direction, for emitting the air outside. A part of whole of each of the ducts is provided in the laminar flow section where a flow of the air is changed into a laminar flow. Since an ion generating section is provided in each of the laminar flow sections, ions generated by the ion generating section can be efficiently involved in the air, so as to increase a concentration of the ions emitted to inside of a room together with the air. | 2012-01-19 |
20120014841 | EXHAUST GAS TREATING CATALYST AND EXHAUST GAS PURIFICATION APPARATUS USING THE SAME - An exhaust gas treating catalyst further improved in denitrification performance is provided. It is an exhaust gas treating catalyst containing a complex oxide represented by the general formula ABO | 2012-01-19 |
20120014842 | DIESEL PARTICLE FILTER WITH IMPROVED BACK PRESSURE CHARACTERISTICS - Proposed is a diesel particle filter which comprises a ceramic wall-flow filter substrate and a coating applied in the inflow ducts, which coating is composed of material with a high melting point. The coating ( | 2012-01-19 |
20120014843 | VEHICLE EXHAUST GAS TREATMENT APPARATUS - A vehicle exhaust gas treatment apparatus includes a DPF with SCR coating. An inlet piping fluidly communicates with the DPF and is positioned generally parallel to the DPF. An outlet pipe fluidly communicates with the DPF and is positioned generally parallel to the DPF. The apparatus is arranged such that exhaust gas flows through the inlet pipe in a first direction from a first inlet pipe end to a second inlet pipe end. The exhaust gas flows through the DPF in a second direction, generally parallel to and opposite to the first direction. The gas flows through the outlet pipe generally in the first direction from a first outlet pipe end to a second outlet pipe end. | 2012-01-19 |
20120014844 | DEVICE FOR ALTERING MOLECULAR BONDS IN FLUIDS - A device for altering molecular bonds in fluids ( | 2012-01-19 |
20120014845 | Biooptical and Biofunctional Properties, Applications and Methods of Polylactic Acid Films - High surface energy materials with low refractive index and UV transparency wherein multilayers of similar or dissimilar materials are thermally fused together to form various functional optical requirements are provided. In some embodiments, a photocatalytic biopolymer structure comprising of a UV transparent biopolymer in integrating fused nanophotocatalytic minerals such as Tio2 used for various applications is provided. Many embodiments are based on the integration of nanophotocatalytic minerals fused to a biopolymer structure in which the biopolymer structure is UV transparent (UVT) and allows UV light to be transmitted through the biopolymer structure activating the nanophotocatalytic fused layer. | 2012-01-19 |
20120014846 | High Energy Reduction in a Propane Dehydrogenation Unit by Utilizing a High Pressure Product Splitter Column - An improved process for the production of olefins, and in particular for separation of olefins produced by a dehydrogenation process from paraffin feed stocks, is provided. A high pressure product splitter is used to separate olefins produced in a dehydrogenation plant from residual paraffin feed stocks. The use of a high pressure splitter to separate olefin products from paraffin feed stocks allows for recovery of a high purity olefin product with lower energy consumption compared to prior art processes. The process is particularly suited to separation of propylene from propane. | 2012-01-19 |
20120014847 | MULTIPHASE CONTACT AND DISTRIBUTION APPARATUS FOR HYDROPROCESSING - Systems and apparatus for mixing, cooling, and distributing multiphase fluid mixtures within a reactor, wherein reactor internal apparatus of the present invention provides not only improved fluid mixing and distribution to each underlying catalyst bed surface, but also offers other advantages including: decreased mixing tray height; easier maintenance, assembly and disassembly; and decreased amounts of fabrication material. In an embodiment, fluid may be evenly distributed to a catalyst bed from a fluid distribution unit comprising a nozzle tray including a plurality of nozzles, wherein the nozzles include at least one liquid inlet disposed tangentially to an inner surface of the nozzle. | 2012-01-19 |
20120014848 | Connection Assembly for Ultra High Pressure Liquid Chromatography - A fitting assembly having a nut, a ferrule, and a ferrule tip that may be assembled by an operator. The fitting assembly includes a nut with first and second ends, with the second end adapted to receive the first end of a ferrule, and a ferrule tip with a first end having an externally tapered portion adapted to abut the second end of the ferrule and a second end adapted to be received in a component or fitting of a liquid chromatography system. The nut, ferrule and ferrule tip of the fitting assembly have passageways therethrough for receiving and removably holding tubing. | 2012-01-19 |
20120014849 | MULTIPHASE CONTACT AND DISTRIBUTION APPARATUS FOR HYDROPROCESSING - Systems and apparatus for mixing, cooling, and distributing multiphase fluid mixtures within a reactor, wherein reactor internal apparatus of the present invention provides not only improved fluid mixing and distribution to each underlying catalyst bed surface, but also offers other advantages including: decreased mixing tray height; easier maintenance, assembly and disassembly; and decreased amounts of fabrication material. In an embodiment, fluid may be evenly distributed to a catalyst bed from a fluid distribution unit comprising a nozzle tray including a plurality of nozzles, wherein the nozzles include at least one liquid inlet disposed tangentially to an inner surface of the nozzle. | 2012-01-19 |
20120014850 | COMBUSTOR FOR REFORMER - A combustor provides heat to a reformer. The combustor includes an inner wall, a thermocouple, a fuel supply tube, a fuel distribution portion and a first oxidation catalytic layer. The inner wall is formed in a shape of a hollow cylinder having a first oxidation portion in a space therein. The thermocouple extends to the first oxidation portion to measure the temperature of the first oxidation portion. The fuel supply tube has a shape of a hollow cylinder surrounding the thermocouple, and has fuel discharge holes formed at a lower portion thereof. The fuel distribution portion is located below the fuel supply tube, and has distribution nozzles through which fuel is distributed. The first oxidation catalytic layer is located beneath the fuel distribution portion. | 2012-01-19 |
20120014851 | Method of Treating a Gaseous Mixture Comprising Hydrogen, Carbon Dioxide and Hydrogen Sulphide - A gaseous mixture, comprising CO | 2012-01-19 |
20120014852 | Membranes and Reactors for CO2 Separation - The present disclosure relates to a system for carbon dioxide separation. The system includes a conducting membrane having two phases. The first phase is a solid oxide porous substrate. The second phase is molten carbonate. The second phase is positioned within the solid oxide porous substrate of the first phase. The system also includes a H | 2012-01-19 |
20120014853 | NEW PROCESS FOR RECOVERING CO2 FROM REGENERATION FLUE GAS COMING FROM A CATALYTIC CRACKING UNIT - The invention describes an integrated process for capturing CO | 2012-01-19 |
20120014854 | NANOPARTICULAR METAL OXIDE/ANATASE CATALYSTS - The present invention concerns a method of preparation of nanoparticular metal oxide catalysts having a narrow particle size distribution. In particular, the invention concerns preparation of nanoparticular metal oxide catalyst precursors comprising combustible crystallization seeds upon which the catalyst metai oxide is co-precipitated with the carrier metal oxide, which crystallization seeds are removed by combustion in a final calcining step. The present invention also concerns processes wherein the nanoparticular metal oxide catalysts of the invention are used, such as SCR (deNOx) reactions of nitrogen oxides with ammonia or urea as reductant, oxidations of alcohols or aldehydes with dioxygen or air to provide aldehydes, ketones or carboxylic acids, and photocatalytic oxidation of volatile organic compounds (VOCs). | 2012-01-19 |
20120014855 | APPARATUS AND PROCESS FOR DECOMPOSING DINITROGEN MONOXIDE IN AN ADIABATIC FIXED BED REACTOR - The invention relates to an apparatus and to a process for decomposing dinitrogen monoxide. The apparatus comprises a gas inlet | 2012-01-19 |
20120014856 | Air Filtration Device - An air purifier has a housing with an inlet for receiving air and an outlet for exhausting air. The housing provides an air flow path for the flow of air in a downstream direction, from the inlet towards the outlet. Particulate pre-filtration is located within the housing downstream from the air inlet. VOC pre-filtration is located within the housing downstream from the particulate pre-filtration. UV filtration is located within the housing downstream from the VOC pre-filtration. VOC post-filtration is located within the housing downstream from the UV filtration. Final particulate filtration is located within the housing downstream from the VOC post-filtration. | 2012-01-19 |
20120014857 | METHODS FOR SYNTHESIZING AMMONIA BORANE - Methods of synthesizing ammonia borane are provided. The methods comprise reacting at least one amine borane with ammonia such that ammonia borane is produced. Ammonia borane has a chemical formula of NH | 2012-01-19 |
20120014858 | HYDROPHOBIC SILICA PARTICLES AND METHODS OF MAKING SAME - A method of preparing hydrophobic silica particles includes the step of reacting together in a single step a mixture of silane ether monomers and organically modified silane ether monomers with a hydrolyzing agent. The method also includes producing hydrophobic silica microparticles and nanoparticles that can include dyes and/or magnetizable components. The silica nanoparticles can be used in the detection, visualization and/or analysis of latent fingerprints. | 2012-01-19 |
20120014859 | METHOD FOR PRODUCING BIS(FLUOROSULFONYL)IMIDE SALT, METHOD FOR PRODUCING FLUOROSULFATE, AND METHOD FOR PRODUCING BIS(FLUOROSULFONYL)IMIDE ONIUM SALT - According to the method for producing bis(fluorosulfonyl)imide salt of the present invention, the method for producing fluorosulfate, and the method for producing bis(fluorosulfonyl)imide onium salt, first, an aqueous solution is prepared by dissolving a mixed liquid containing bis(fluorosulfonyl)imide and fluorosulfonic acid in water. Then, the aqueous solution is neutralized with an alkaline compound, producing bis(fluorosulfonyl)imide salt and fluorosulfate. In the methods, bis(fluorosulfonyl)imide salt, fluorosulfate, and bis(fluorosulfonyl)imide onium salt can be obtained safely and easily. | 2012-01-19 |
20120014860 | METHOD FOR RECOVERING NITRIC ACID AND PURIFYING SILVER NITRATE ELECTROLYTE - A processes for the regeneration of a silver nitrate and nitric acid based electrolyte as used in certain silver refining processes is based on the hydrolytic removal of undesired metal-based compounds such as water insoluble hydrolysable base metal cations and water insoluble hydrolysable base metal nitrates from which the soluble silver nitrate and nitric acid based electrolyte may be separated. Water is added slowly to a dewatered electrolyte melt held at a predetermined, elevated, temperature while allowing nitric acid thereby formed to evolve and be separated from the melt while the water insoluble base metal salts are formed. The melt is then diluted with water to dilute the silver nitrate contained therein and the insoluble base metal salts are separated from the mixture by filtration. | 2012-01-19 |
20120014861 | CO2 RECOVERY UNIT AND METHOD THEREFOR | 2012-01-19 |
20120014862 | GRAPHITE MATERIAL - A graphite material includes a plurality of graphite particles and a plurality of pores. The plurality of graphite particles and the plurality of pores form a microstructure. A ratio of an elastic modulus to a compression strength of the graphite material ranges from 109 to 138. Preferably, a ratio of a total area of the pores to a whole area of the graphite material in a cross-section of the graphite material ranges from 17.94% to 19.97%. | 2012-01-19 |
20120014863 | PROCESS AND PLANT FOR PRODUCING METAL OXIDE FROM METAL SALTS - A process for producing metal oxide from metal salts includes cleaning a metal salt in a filter. After cleaning, the metal salt is dried in a drying apparatus. Steam is formed in the drying apparatus. The metal salt is preheated in at least one preheating stage. The metal salt is calcined to metal oxide in a fluidized-bed reactor. The metal oxide is cooled. The steam formed in the drying apparatus is recirculated into the filter. | 2012-01-19 |
20120014864 | HYBRID FOAM/LOW-PRESSURE AUTOTHERMAL REFORMER - An autothermal reformer ( | 2012-01-19 |
20120014865 | Copper Containing ZSM-34, OFF And/Or ERI Zeolitic Material For Selective Reduction Of NOx - Described is a copper containing ZSM-34, OFF and/or ERI zeolitic material having a silica to alumina mole ratio ranging from about 4 to about 50 and a copper content, reported as CuO, ranging from about 1 to about 10 wt.-%, based on the total weight of the calcined zeolitic material, and having an alkali metal content, reported as metal oxide, ranging from about 1.5 to about 12 wt.-%. | 2012-01-19 |
20120014866 | Copper Containing ZSM-34, OFF And/Or ERI Zeolitic Material For Selective Reduction Of NOx - Described is a copper containing ZSM-34, OFF and/or ERI zeolitic material having a silica to alumina mole ratio ranging from about 4 to about 50 and a copper content, reported as CuO, ranging from about 1 to about 10 wt.-%, based on the total weight of the calcined zeolitic material, and having an alkali metal content, reported as the metal oxide, ranging from about 0.7 to about 1.5 wt.-%, wherein the 750° C.-aged copper containing ZSM-34, OFF and/or ERI zeolitic material exhibits NO conversion at 200° C. of at least about 75% and at 450° C. of at least about 90%, measured at a gas hourly volume based space velocity of 30000 h | 2012-01-19 |
20120014867 | Copper Containing ZSM-34, OFF And/Or ERI Zeolitic Material For Selective Reduction Of NOx - Described is a copper containing ZSM-34, OFF and/or ERI zeolitic material having a silica to alumina mole ratio ranging from about 4 to about 50 and a copper content, reported as CuO, ranging from about 1 to about 10 wt.-%, based on the total weight of the calcined zeolitic material, and having an alkali metal content, reported as the metal oxide, of less than about 0.7 wt.-%. | 2012-01-19 |
20120014868 | METHODS TO DIAGNOSE DEGENERATIVE DISC DISEASE - Methods are provided that better describe, and localize the pain generator or suspected pain generator in and around spinal discs in relation to neck or back pain so as to improve the diagnosis of degenerative disc disease. In some embodiments, there are methods for diagnosing a pain generator or a suspected pain generator in a patient suffering from back pain, the methods comprise labeling an inflammatory, vascular, neuronal, and/or metabolic pain marker at a location inside of or adjacent to an intervertebral disc in the patient suffering from back pain to increase an image of the pain marker with an imaging procedure; and imaging the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a manner sufficient to diagnose the pain generator or suspected pain generator. | 2012-01-19 |
20120014869 | MUC18 TARGETING PEPTIDES - Provided are MUC 18 targeting peptides which may be used, e.g., to therapeutically target B-I lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC 18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer. | 2012-01-19 |
20120014870 | Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody - With dedicated research, the present inventors discovered that not only the LGR7 gene but also the LGR7 protein are highly expressed in clear cell adenocarcinoma cells of ovarian cancer. Furthermore, the present inventors found that anti-LGR7 antibodies have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. From the above findings, the present inventors discovered that the anti-LGR7 antibodies are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear cell adenocarcinoma. | 2012-01-19 |
20120014871 | Ovarian Cancer Methylome - The present invention provides methods and kits for identifying a cell that exhibits or is predisposed to exhibiting unregulated growth by detecting hypermethylation of a gene or a regulatory region in at least one gene in the cell. Also provided are methods for diagnosis or prognosis of ovarian cancer in a subject. Also provided are methods of ameliorating ovarian cancer in a subject by administering to the subject an agent that demethylates a hypermethylated gene or regulatory region thereof. | 2012-01-19 |
20120014872 | Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers - The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer. | 2012-01-19 |
20120014873 | PEPTIDES WHOSE UPTAKE BY CELLS IS CONTROLLABLE - A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. X may be cleaved extracellularly or intracellularly. The molecules of the present invention may be linear, cyclic, branched, or have a mixed structure. | 2012-01-19 |
20120014874 | PHOTOSENSITIZER-METAL NANOPARTICLE CHARGE COMPLEX AND COMPOSITION CONTAINING THE COMPLEX FOR PHOTODYNAMIC THERAPY OR DIAGNOSIS - Provided are a photosensitizer-metal nanoparticle charge complex and a composition for photodynamic therapy or diagnosis containing the same. The complex includes a metal nanoparticle, a photosensitizer charged with a first charge, and a linker bound to the metal nanoparticle and charged with a second charge having an opposite polarity to the first charge. During circulation in blood, the photosensitizer-metal nanoparticle charge complex is maintained in a complex type, and thus duration of a side effect of photosensitivity can be reduced. In a tumor tissue, the complex is specifically accumulated, but in a normal tissue, it is difficult for the complex to penetrate. Thus, the complex can selectively destroy the tumor tissue. Moreover, selective fluorescence in the tumor tissue can provide further improvement in accuracy of diagnosing a tumor using the complex. | 2012-01-19 |
20120014875 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 2012-01-19 |
20120014876 | ANTAGONISTIC PEPTIDES FOR FRIZZLED-1 AND FRIZZLED-2 - The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled 2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue. | 2012-01-19 |
20120014877 | COMPOSITIONS AND METHODS TO TREAT CANCER WITH CpG RICH DNA AND CUPREDOXINS - The present invention relates to compositions comprising CpG rich DNA from | 2012-01-19 |
20120014878 | Synthesis of Oligonucleotide Mediated Gold Core- Silver Shell Nanoparticles - The present invention relates to synthesis of oligonucleotide mediated gold core- silver shell nanoparticles and testing their SERS performance. A Raman reporter molecule and twelve-base long oligonucleotide are simultaneously attached on gold nanoparticles and a silver layer is deposited on the modified gold nanoparticles. The SERS performance of gold core- silver shell nanoparticles (CSNPs) is much greater than the CSNPs prepared without oligonucleotides and the same size non-modified gold nanoparticles after silver staining. | 2012-01-19 |
20120014879 | USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION - Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients. | 2012-01-19 |
20120014880 | METHOD FOR THE PREVENTION AND TREATMENT OF ESSENTIAL TREMOR BY REGULATING alpha1G T-TYPE CALCIUM CHANNEL OR BY T-TYPE CALCIUM CHANNEL BLOCKERS - The present invention relates to a method for the prevention and treatment of essential tremor by blocking α1G T-type calcium channel, a preventive and therapeutic agent for essential tremor containing the α1G T-type calcium channel blocker as an active ingredient, and a screening method of a preventive and therapeutic agent for essential tremor by investigating α1G T-type calcium channel blocking activity. More precisely, the present invention relates to a method for the prevention and treatment of essential tremor by using α1G T-type calcium channel blocker, for which the inventors confirmed that the α1G T-type calcium channel knock out mice (α1G−/−) had resistance against essential tremor and when the T-type channel blocker was administered to the wild type mice (α1G+/+), they gained resistance against essential tremor. | 2012-01-19 |
20120014881 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 2012-01-19 |
20120014882 | SKIN CARE COMPOSITIONS - Anhydrous sunscreen compositions that include a volatile solvent, an organic UV-filter dissolved in the volatile solvent, a water-insoluble, low-volatility, C | 2012-01-19 |
20120014883 | Compositions Comprising Derivatives Of Essential Oil Compounds And Use In Personal Care Products - Compositions containing one or more derivatives of essential oil compounds for use in personal care compositions, such as compositions for oral, throat and skin care are disclosed. These derivatives include acetals of parent essential oil aldehydes and ketones; esters or ethers of parent essential oil alcohols and phenolics; and esters of parent essential oil acids. Examples of parent essential oil aldehydes and ketones include citral, cinnamic aldehyde, ρ-anisaldehyde, vanillin, ethyl vanillin, heliotropin, carvone, and menthone. Examples of parent essential oil alcohols and phenolics include thymol, eugenol, isoeugenol, dihydroeugenol, carvacrol, carveol, geraniol, nerol, vanillyl alcohol, heliotropyl alcohol, ρ-anisyl alcohol, cinnamyl alcohol and β-ionol. Examples of parent essential oil acids include ρ-anisic acid, cinnamic acid, vanillic acid and geranic acid. The present compositions comprising essential oil derivatives are useful as base flavor or base perfume for incorporation into personal care products and to provide other benefits including antimicrobial efficacy. Optionally the compositions will contain additional antimicrobially- or anti-inflammatory-effective components including those also derived from plant essential oils or synthetic versions thereof. | 2012-01-19 |
20120014884 | MENTHOL-DERIVATIVE COMPOUNDS AND USE THEREOF AS ORAL AND SYSTEMIC ACTIVE AGENTS - The present invention discloses novel uses of specific menthol-derivative compounds of Formula 1, and compositions thereof, for methods of providing oral and systemic health care benefits, and methods of up-regulating or down-regulating periodontal disease metabolites: Formula 1 wherein, X is an oxygen atom or an NH radical; and R is an unsubstituted or substituted aryl or aliphatic radical. In some embodiments, the oral and systemic health care benefits include biofilm anti-attachment, anti-inflammation, anti-oxidant, anti-bone loss, and anti-microbial benefits. In some embodiments, the periodontal disease metabolites correspond to healthy and/or diseased oral status and allow differential diagnosis of oral health. | 2012-01-19 |
20120014885 | Personal Care Compositions and Methods for Their Use - The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments, the present invention provides compositions for use in skin and/or hair care, as well as cosmetic compositions. In alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI. | 2012-01-19 |
20120014886 | SOOTHING COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE WHICH ACTIVATES HMG-COA REDUCTASE - The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R | 2012-01-19 |
20120014887 | NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES - The present invention concerns a peptide of following formula I: R being a side chain having at least one heteroatom selected from sulfur, nitrogen and oxygen in a carbonyl form (C═O); R | 2012-01-19 |
20120014888 | Matte Skin Finish Compositions - A composition and method for reducing the shine of human skin is disclosed. The composition imparts a topical matte finish to the skin for an extended time period. The composition contains polymeric microparticles, optionally loaded with a cosmetic or therapeutic skin care compound. | 2012-01-19 |
20120014889 | METHODS FOR MAKING 1,3-DIHYDROXYACETONE (DHA) FROM GLYCEROL - A method comprising reacting glycerol with acetaldehyde or 1,1-diethoxyethane to produce 1,3-dihydroxyacetone (DHA), without using fermentation or direct oxidation of the glycerol is provided. DHA is useful in various products, including as a sunless tanning agent. | 2012-01-19 |
20120014890 | Coffee Cherry Cosmetic Composition and Methods - A cosmetic composition comprises a coffee cherry preparation, and most preferably an extract from a sub-ripe quick-dried coffee cherry. Particularly contemplated cosmetic compositions are formulated as a shampoo, lotion, cream, balm, or ointment, and will have at least one of an antioxidant effect, an anti-inflammatory effect, a UV-protective effect, an antimutagenic effect, a chemoprotective effect, a scar reducing effect, a skin-lightening effect, a moisturizing effect, a wrinkle reduction effect, and an antibacterial effect. | 2012-01-19 |
20120014891 | SUNSCREEN PRODUCT COMPRISING HYDROXYAPATITE AS PHYSICAL FILTER - The present invention concerns the use of hydroxyapatite as the physical sunscreening agent in synergistic association with at least one chemical sunscreening agent, in products designed for application to the skin in order to protect the same from solar UV radiation. Particularly, cosmetic compositions are described comprising the sunscreen product having screening capability, high dermal tolerance and a low whitening effect on the skin. | 2012-01-19 |
20120014892 | NAIL-HARDENING COSMETIC COMPOSITION, USE OF ALDEHYDES TO HARDEN AND STRENGTHEN NAILS, AND METHOD FOR APPLYING SAME - A cosmetic composition for nails containing a concentration less than or equal to 1 wt % of at least one monoaldehyde of the formula (I): R—CHO, where R is a C5-C12 linear alkyl radical or a C5-C12 alkenyl with an unconjugated double bond to the —CHO aldehyde group, as nail hardening agent, and provided in the form of a colored or colorless fingernail polish, a polish undercoat, a peelable polish, a beauty oil, an emulsion or an aqueous solution, or a gel. Also the use of aldehydes of the formula (I) for hardening and strengthening nails and to a method for applying same. | 2012-01-19 |
20120014893 | ANTIMYCOTIC PHARMACEUTICAL COMPOSITION - In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60° C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture. | 2012-01-19 |
20120014894 | Compositions and Methods for Treating Hyperpigmentation - This invention provides compositions and methods for reducing hyperpigmentation. In preferred embodiments, the compositions are topical compositions that contain kojic acid and a carrier molecule for enhancing the transdermal penetration of kojic acid. This invention also provides kits for treating hyperpigmentation. | 2012-01-19 |
20120014895 | Lip Cosmetics - The present invention provides a lip cosmetic that has good gloss and good stability, while maintaining post-application secondary adhesion resistance. The lip cosmetic of the present invention is characterized by comprising the following components (a) to (d):
| 2012-01-19 |
20120014896 | ANTIMICROBIAL COMPOSITIONS CONTAINING ESSENTIAL OILS - Compositions for cleaning, disinfecting and sanitizing are described. The compositions comprise essential oils and are stable, non-toxic and environmentally sustainable. Also disclosed are deodorants and scalp refreshers having these properties. | 2012-01-19 |
20120014897 | WATER-FREE ANTIPERSPIRANT SPRAYS WITH IMPROVED SUBSTANCE RELEASE - An antiperspirant composition for personal hygiene is formulated as a suspension which can be sprayed with or without a propellant, and contains at least one antiperspirant substance, 0-5 wt. % free water, based on the weight of the propellant-free composition, and triethylcitrate and at least one additional cosmetic oil, which is liquid under normal conditions, as a carrier. The weight fraction of the triethylcitrate with respect to the total amount of oils is between 13-50 wt. % based on the total weight of the propellant-free composition. The composition also includes and 0 to less than 1 wt. % cyclomethicone, based on the weight of the propellant-free composition. | 2012-01-19 |
20120014898 | COMPOSITION FOR PREVENTING HAIR LOSS AND STIMULATING HAIR GROWTH - The present invention relates to the use of a composition comprising a compound of the formula I: | 2012-01-19 |
20120014899 | COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND FILLERS - The invention relates to a cosmetic method for making-up and/or caring for keratin materials, in particular the skin, whereby a cosmetic composition is applied to the keratin materials, said cosmetic composition comprising siloxane resins and fillers. In particular, the invention relates to compositions used to care for or make-up the aforementioned keratin materials. | 2012-01-19 |
20120014900 | Personal Care Composition Comprising a Near-Terminal Branched Compound - A personal care composition comprising: a near-terminal branched compound according to Formula I; a cosmetically acceptable aqueous carrier; wherein the near-terminal branched compound is not comprised in a gel network. | 2012-01-19 |
20120014901 | Rinse-Off Conditioning Composition Comprising a Near-Terminal Branched Alcohol - A rinse-off conditioning composition comprising: (a) near-terminal branched alcohol according to Formula I; (b) a cationic surfactant; (c) a terminal aminosilicone; wherein the near-terminal branched alcohol and the cationic surfactant are comprised in a lamellar gel matrix. | 2012-01-19 |
20120014902 | COMPOSITIONS AND THEIR USE - Aqueous compositions, methods of manufacturing such aqueous compositions, and methods of removing reducing and/or suppressing malodours using such aqueous compositions are described. These compositions utilize a combination of hydrogen peroxide, a source of copper II, nonionic surfactant and alcohol to provide a highly effective and stable malodour removing, reducing and/or suppressing composition. The compositions are particularly useful as aerosol compositions for effective malodour removal, reduction and/or suppression in particular malodours from open sites such as landfill and in closed domestic environments such as the home. Also described is a stabilized hydrogen peroxide solution, which is stable on the addition of copper (II) salts. | 2012-01-19 |
20120014903 | Cleaning Solution and Related Methods of Use - Disclosed is a substance and related methods for cleaning electronic devices which are to be used successively by different human operators. | 2012-01-19 |
20120014904 | VASCULAR DELIVERY SYSTEMS - The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells. | 2012-01-19 |
20120014905 | CONUGATED PROTEINS AND PEPTIDES - Novel compounds of the general formula (I): in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R | 2012-01-19 |
20120014906 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 2012-01-19 |
20120014907 | USE OF SUBSTITUTED CYANOPYRROLIDINES AND COMBINATION PREPARATIONS CONTAINING THEM FOR TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES - Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantly; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier. | 2012-01-19 |
20120014908 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF - The present disclosure provides inter alia conjugates of formula (I): wherein n, R1, R2, Rx, Z, X, Y and Z are as defined herein. A conjugate of formula (I) can also be converted to a conjugate of formulae (II) or (III) as described herein. Without limitation, the conjugates can be used to make controlled release materials and chemical sensors. | 2012-01-19 |
20120014909 | TISSUE ADHESIVE AND SEALANT COMPRISING POLYGLYCEROL ALDEHYDE - A tissue adhesives and sealant formed by reacting a polyglycerol aldehyde with a water-dispersible, multi-arm amine is described. The tissue adhesive and sealant may be useful for medical and veterinary applications, including, but not limited to, wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions. | 2012-01-19 |
20120014910 | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS ASSOCIATED WITH MENOPAUSE, HORMONAL VARIATIONS AND ARTHRITIS - The invention provides for compositions and methods of treating or ameliorating menopausal symptoms and/or symptoms associated with hormonal variations by administering granulocyte colony-stimulating factor (G-CSF). The invention also provides for compositions and methods of treating or ameliorating arthritis using G-CSF. | 2012-01-19 |
20120014911 | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor - The present invention includes compositions and methods for modulating a regulator of IFNAR1. The invention includes inhibitors and activators of PERK, PTP1B, and/or PKD2 wherein inhibition, or activation, of at least one of PERK, PTP1B, and PKD2 modulates the stability of IFNAR1. | 2012-01-19 |
20120014912 | PALATABLE PHARMACEUTICAL COMPOSITION - A pharmaceutical formulation comprising:
| 2012-01-19 |
20120014913 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS - This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions. | 2012-01-19 |
20120014914 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES - The present invention relates to compounds of formula I: | 2012-01-19 |
20120014915 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post | 2012-01-19 |
20120014916 | POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF - The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C. | 2012-01-19 |
20120014917 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS - The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof. | 2012-01-19 |
20120014918 | ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure is directed to novel water-soluble pharmaceutically acceptable, crystalline addition salts of (i) an amine containing one or more hydroxyl and/or carboxylic groups with (ii) amino nicotinic acid derivatives of formula (I) | 2012-01-19 |
20120014919 | MODULATION OF SOCS EXPRESSION IN THERAPEUTIC REGIMENS - A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein certain physiological processes normally associated with cytokine administration (e.g. the induction of SOCS 1 and/or SOCS 3) are diminished or eliminated. The method comprises continuously administering a controlled dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. | 2012-01-19 |
20120014920 | ANNEXIN AND ITS USE TO TREAT INFLAMMATORY DISORDERS - There is provided a composition comprising an effective amount of Annexin A | 2012-01-19 |
20120014921 | TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS VIA INTRANASAL ADMINISTRATION OF UMBILICAL CORD-DERIVED CELLS - This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients. | 2012-01-19 |
20120014922 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 2012-01-19 |
20120014923 | HYPOGLYCEMIC EFFECT ENHANCER - A hypoglycemic effect enhancer for enhancing the activity of an α-glucosidase inhibitor, the enhancer comprising at least one kind of bacteria selected from the group consisting of bifidobacteria, lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria. | 2012-01-19 |
20120014924 | Compositions and Methods for Improving the Functional Efficacy of Stem Cell-Derived Cardiomyocytes - This invention provides an isolated stem cell modified to provide, enhance or contain the functional characteristics of the sarcoplasmic reticulum (SR) The isolated stem cells are modified by expressing a calcium channel protein, by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein, by inhibiting or downregulating expression of the Na+/Ca2+ exchanger (NCX) protein, by expressing a calcium handling protein, by expressing a transverse (t)-tubule, and/or by expressing a transverse (t)-tubule biogenic protein The modified cells may be expanded to a substantially homogenous population of these cells or differentiated to a more mature cell type Compositions are also provided The cells and compositions can be administered to a host and used to regenerate cardiac tissue, improve cardiac function, restore action potential of cardiac tissue, and treat or prevent cardiac malfunction Use for diagnostic screening of therapeutic candidates is also provided | 2012-01-19 |
20120014925 | Self-Assembling Peptides Incorporating Modifications and Methods of Use Thereof - The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides. | 2012-01-19 |
20120014926 | Activation of Precursor Cells for Cell Therapy - This invention relates to a method and compositions for activation of precursor cells via upregulation of CXCR4 surface receptor expression, to give the activated cells a better homing capability and higher viability. The method for activation involves incubation of the target cells with an isotonic activation solution containing an activation-effective amount of calcium. Such activated cells have a better ability to engraft into target tissues to execute the therapeutic function. | 2012-01-19 |
20120014927 | METHODS AND KITS FOR DETERMINING PREDISPOSITION TO CANCER - Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer. | 2012-01-19 |
20120014928 | METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION - Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. | 2012-01-19 |
20120014929 | STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 2012-01-19 |
20120014930 | STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 2012-01-19 |
20120014931 | HUMAN LATE STAGE MOTOR NEURON PROGENITOR CELLS - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells. | 2012-01-19 |